Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2355) 2355
Book Chapter (94) 94
Dissertation (19) 19
Publication (6) 6
Book / eBook (2) 2
Magazine Article (2) 2
Conference Proceeding (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (1776) 1776
life sciences & biomedicine (1747) 1747
efficacy (1575) 1575
humans (1564) 1564
female (955) 955
male (871) 871
safety (715) 715
treatment outcome (674) 674
middle aged (657) 657
adult (651) 651
aged (480) 480
clinical trials (439) 439
biological and medical sciences (391) 391
medical sciences (354) 354
pharmacology & pharmacy (325) 325
drug therapy (280) 280
double-blind method (275) 275
self efficacy (270) 270
care and treatment (269) 269
adolescent (248) 248
analysis (233) 233
psychiatry (233) 233
studies (224) 224
patients (222) 222
oncology (221) 221
research (206) 206
immunology (190) 190
social sciences (189) 189
animals (181) 181
health aspects (177) 177
quality of life (174) 174
young adult (171) 171
pharmacology. drug treatments (167) 167
neurosciences & neurology (161) 161
time factors (149) 149
aged, 80 and over (145) 145
randomized controlled trials as topic (144) 144
prospective studies (142) 142
clinical neurology (141) 141
medical research (136) 136
tolerability (130) 130
psychology (128) 128
dose-response relationship, drug (127) 127
cancer (126) 126
follow-up studies (125) 125
medicine & public health (121) 121
child (120) 120
review (111) 111
abridged index medicus (107) 107
drug therapy, combination (107) 107
infectious diseases (106) 106
general & internal medicine (104) 104
risk factors (104) 104
systematic review (104) 104
medicine, research & experimental (102) 102
research & experimental medicine (102) 102
drug dosages (101) 101
severity of illness index (100) 100
meta-analysis (99) 99
internal medicine (96) 96
children (94) 94
medicine, experimental (94) 94
retrospective studies (94) 94
drug administration schedule (93) 93
pharmacokinetics (93) 93
intervention (92) 92
effectiveness (91) 91
self-efficacy (91) 91
surveys and questionnaires (91) 91
chemotherapy (90) 90
medicine, general & internal (90) 90
usage (85) 85
pain (84) 84
medicine (83) 83
clinical trials as topic (82) 82
dosage and administration (82) 82
neurosciences (81) 81
schizophrenia (81) 81
vaccines (81) 81
health care sciences & services (77) 77
tumors (77) 77
cardiovascular system & cardiology (75) 75
drugs (73) 73
psychology. psychoanalysis. psychiatry (73) 73
toxicity (73) 73
mental depression (72) 72
patient outcomes (70) 70
public, environmental & occupational health (69) 69
surgery (69) 69
pediatrics (68) 68
comparative analysis (67) 67
fundamental and applied biological sciences. psychology (67) 67
antidepressants (66) 66
asthma (66) 66
statistical analysis (66) 66
allergy (65) 65
child, preschool (65) 65
dermatology (64) 64
pharmacology (64) 64
side effects (64) 64
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2467) 2467
Japanese (6) 6
Russian (6) 6
Spanish (5) 5
German (4) 4
Chinese (3) 3
Korean (2) 2
Dutch (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Time to Review the Role of Surrogate End Points in Health Policy: State of the Art and the Way Forward
by Ciani, Oriana, PhD and Buyse, Marc, ScD and Drummond, Michael, PhD and Rasi, Guido, PhD and Saad, Everardo D., MD and Taylor, Rod S., PhD
Value in health, ISSN 1098-3015, 2017, Volume 20, Issue 3, pp. 487 - 495
Internal Medicine | health technology assessment | clinical outcome assessment | surrogate end points | validation | Economics | Social Sciences | Life Sciences & Biomedicine | Health Care Sciences & Services | Business & Economics | Health Policy & Services | Science & Technology | Quality-Adjusted Life Years | Disease-Free Survival | Medical Oncology | United States | Humans | Biomarkers | Treatment Outcome | Clinical Trials as Topic | Evidence-Based Medicine | Health Policy | United States Food and Drug Administration | Technology Assessment, Biomedical | Drugs | Medical technology | Health professional-Patient communication | Health care policy | Clinical trials | Clinical research | Efficacy | Coverage | Medical supplies | Patients | Clinical outcomes | Morbidity | Policy making | Validity | Biological markers | Surrogates | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Analyses of Efficacy End Points in a Controlled Trial of Interferon-γ1b for Idiopathic Pulmonary Fibrosis
by King, Talmadge E and Safrin, Sharon and Starko, Karen M and Brown, Kevin K and Noble, Paul W and Raghu, Ganesh and Schwartz, David A
Chest, ISSN 0012-3692, 01/2005, Volume 127, Issue 1, pp. 171 - 177
mortality | efficacy end points | idiopathic pulmonary fibrosis | percentage of predicted FVC | arterial-alveolar pressure gradient | Percentage of predicted FVC | Arterial-alveolar pressure gradient | Efficacy end points | Idiopathic pulmonary fibrosis | Mortality | Cardiology. Vascular system | Antiviral agents | Respiratory system : syndromes and miscellaneous diseases | Pharmacology. Drug treatments | Biological and medical sciences | Medical sciences | Antibiotics. Antiinfectious agents. Antiparasitic agents | Pneumology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Overview on coenzyme Q10 as adjunctive therapy in chronic heart failure. Rationale, design and end‐points of “Q‐symbio” ‐ A multinational trial
by Mortensen, Svend Aage
BioFactors (Oxford), ISSN 0951-6433, 2003, Volume 18, Issue 1‐4, pp. 79 - 89
heart failure | coenzyme Q10 | clinical trials | safety | efficacy | Heart failure | Clinical trials | Coenzyme Q | Efficacy | Safety | Coenzymes | Double-Blind Method | Cardiac Output, Low - mortality | Humans | Ubiquinone - analogs & derivatives | Placebos | Ubiquinone - therapeutic use | Treatment Outcome | Cardiac Output, Low - drug therapy | Controlled Clinical Trials as Topic | Ubiquinone - adverse effects | Randomized Controlled Trials as Topic | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Safety and efficacy of cerebral protection devices in transcatheter aortic valve replacement: A clinical end-points meta-analysis
by Mohananey, Divyanshu and Sankaramangalam, Kesavan and Kumar, Arnav and Jobanputra, Yash and Villablanca, Pedro and Krishnaswamy, Amar and Mick, Stephanie and Svensson, Lars G and Tuzcu, E. Murat and Kapadia, Samir R
Cardiovascular revascularization medicine, ISSN 1553-8389, 10/2018, Volume 19, Issue 7, pp. 785 - 791
Stroke | Cerebral embolic protection | Safety and efficacy | TAVR | Stroke (Disease) | Heart valve diseases | Health aspects | Mortality | Cardiovascular agents
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text New drugs and patient-centred end-points in old age: setting the wheels in motion
by Mangoni, Arduino A and Pilotto, Alberto
Expert review of clinical pharmacology, ISSN 1751-2433, 01/2016, Volume 9, Issue 1, pp. 81 - 89
frailty | functional status | pharmacodynamics | safety | therapeutic goals | drug development | older adults | pharmacokinetics | efficacy | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Acute Disease | Drugs, Investigational - adverse effects | Age Factors | Patient-Centered Care - methods | Humans | Endpoint Determination | Drugs, Investigational - therapeutic use | Aged | Frail Elderly | Health Status | Chronic Disease | Disabled Persons
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Reduction in Total Cardiovascular Events with Ezetimibe/Simvastatin Post-Acute Coronary Syndrome the IMPROVE-IT Trial
by Murphy, Sabina A and Cannon, Christopher P and Blazing, Michael A and Giugliano, Robert P and White, Jennifer A and Lokhnygina, Yuliya and Reist, Craig and Im, Kyungah and Bohula, Erin A and Isaza, Daniel and Lopez-Sendon, Jose and Dellborg, Mikael and Kher, Uma and Tershakovec, Andrew M and Braunwald, Eugene and Sahlgrenska akademin and Institute of Medicine and Göteborgs universitet and Gothenburg University and Sahlgrenska Academy and Institutionen för medicin
Journal of the American College of Cardiology, ISSN 0735-1097, 02/2016, Volume 67, Issue 4, pp. 353 - 361
simvastatin | ezetimibe | low-density lipoprotein cholesterol | total events | Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Myocardial Infarction - blood | United States - epidemiology | Myocardial Infarction - epidemiology | Survival Rate - trends | Follow-Up Studies | Simvastatin - administration & dosage | Humans | Middle Aged | Cholesterol, LDL - drug effects | Male | Treatment Outcome | Ezetimibe - administration & dosage | Acute Coronary Syndrome - blood | Incidence | Acute Coronary Syndrome - drug therapy | Dose-Response Relationship, Drug | Time Factors | Anticholesteremic Agents - administration & dosage | Cholesterol, LDL - blood | Female | Aged | Myocardial Infarction - prevention & control | Drug Therapy, Combination | Coronary artery bypass | Low density lipoproteins | Analysis | Cardiac patients | Heart attack | Anticholesteremic agents | Index Medicus | Abridged Index Medicus | metaanalysis | moderate statin therapy | high-risk | Klinisk medicin | atorvastatin | end-points | efficacy | Clinical Medicine | myocardial-infarction | cholesterol | randomized-trials
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Ophthalmic medicine regulatory approvals through the European Centralised Procedure, 1999–2017: Clinical efficacy considerations
by Morgan-Warren, Peter J
European journal of ophthalmology, ISSN 1120-6721, 3/2020, Volume 30, Issue 2, pp. 321 - 349
clinical trials | Centralised Procedure | efficacy | end-points | Regulatory approval | Life Sciences & Biomedicine | Ophthalmology | Science & Technology | Drug Approval - statistics & numerical data | Ophthalmology - statistics & numerical data | Risk Assessment | European Union | Humans | Treatment Outcome | Retrospective Studies
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects
by Heerspink, Hiddo J. L and Desai, Mehul and Jardine, Meg and Balis, Dainius and Meininger, Gary and Perkovic, Vlado
Journal of the American Society of Nephrology, ISSN 1046-6673, 01/2017, Volume 28, Issue 1, pp. 368 - 375
TRIAL | ATRIAL-NATRIURETIC-PEPTIDE | GLUCOSE CONTROL | GFR DECLINE | EFFICACY | SAFETY | DOUBLE-BLIND | END-POINTS | CHRONIC KIDNEY-DISEASE | EMPAGLIFLOZIN | Life Sciences & Biomedicine | Urology & Nephrology | Science & Technology | Hypoglycemic Agents - therapeutic use | Albuminuria - etiology | Double-Blind Method | Canagliflozin - pharmacology | Diabetic Nephropathies - etiology | Humans | Middle Aged | Sulfonylurea Compounds - therapeutic use | Male | Albuminuria - prevention & control | Disease Progression | Sodium-Glucose Transporter 2 - antagonists & inhibitors | Hypoglycemic Agents - pharmacology | Canagliflozin - therapeutic use | Sulfonylurea Compounds - pharmacology | Female | Diabetes Mellitus, Type 2 - drug therapy | Diabetic Nephropathies - prevention & control | Diabetes Mellitus, Type 2 - complications | Index Medicus | renal function | Clinical Research | SGLT2 | diabetic nephropathy | canagliflozin
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Effect of sacubitril/valsartan on recurrent events in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM‐HF)
by Mogensen, Ulrik M and Gong, Jianjian and Jhund, Pardeep S and Shen, Li and Køber, Lars and Desai, Akshay S and Lefkowitz, Martin P and Packer, Milton and Rouleau, Jean L and Solomon, Scott D and Claggett, Brian L and Swedberg, Karl and Zile, Michael R and Mueller‐Velten, Guenther and McMurray, John J.V and Sahlgrenska akademin and Institute of Medicine, Department of Molecular and Clinical Medicine and Institutionen för medicin, avdelningen för molekylär och klinisk medicin and Göteborgs universitet and Gothenburg University and Sahlgrenska Academy
European journal of heart failure, ISSN 1388-9842, 04/2018, Volume 20, Issue 4, pp. 760 - 768
Heart failure | Hospitalization | Recurrent events | Neprilysin inhibitor | Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Morbidity - trends | Recurrence | United States - epidemiology | Prospective Studies | Survival Rate - trends | Humans | Middle Aged | Heart Failure - physiopathology | Stroke Volume - physiology | Europe - epidemiology | Male | Angiotensin-Converting Enzyme Inhibitors - administration & dosage | Heart Failure - drug therapy | Dose-Response Relationship, Drug | Tetrazoles - administration & dosage | Female | Aged | Aminobutyrates - administration & dosage | Enalapril - administration & dosage | Angiotensin Receptor Antagonists - administration & dosage | Heart Failure - mortality | Index Medicus | Focus on Prognostic Variables | enalapril | time data | efficacy | Kardiologi | Cardiac and Cardiovascular Systems | clinical-trials | regression | model | receptor neprilysin inhibition | composite end-points | hospitalizations
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Site enrollment rate, outcomes, and study drug effects in a multicenter trial. Results from RELAX-AHF
by Metra, Marco and Davison, Beth A and Gimpelewicz, Claudio and Carubelli, Valentina and Felker, G. Michael and Filippatos, Gerasimos and Greenberg, Barry H and Hua, Tsushung A and Liu, Zoe and Pang, Peter S and Ponikowski, Piotr and Severin, Thomas M and Voors, Adriaan A and Wang, Yi and Cotter, Gad and Teerlink, John R
International journal of cardiology, ISSN 0167-5273, 02/2018, Volume 253, pp. 91 - 96
Clinical trials | Prognosis | Site selection | Acute heart failure | EVEREST EFFICACY | ACUTE HEART-FAILURE | MANAGEMENT | CLINICAL-TRIALS | GLOBALIZATION | TOLVAPTAN | END-POINTS | VASOPRESSIN ANTAGONISM | Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Natriuretic peptides | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Meta-analyses of ataluren randomized controlled trials in nonsense mutation Duchenne muscular dystrophy
by Campbell, Craig and Barohn, Richard J and Bertini, Enrico and Chabrol, Brigitte and Comi, Giacomo Pietro and Darras, Basil T and Finkel, Richard S and Flanigan, Kevin M and Goemans, Nathalie and Iannaccone, Susan T and Jones, Kristi J and Kirschner, Janbernd and Mah, Jean K and Mathews, Katherine D and McDonald, Craig M and Mercuri, Eugenio and Nevo, Yoram and Pereon, Yann and Ben Renfroe, J and Ryan, Monique M and Sampson, Jacinda B and Schara, Ulrike and Sejersen, Thomas and Selby, Kathryn and Tulinius, Mar and Vilchez, Juan J and Voit, Thomas and Wei, Lee-Jen and Wong, Brenda L and Elfring, Gary and Souza, Marcio and McIntosh, Joseph and Trifillis, Panayiota and Peltz, Stuart W and Muntoni, Francesco and Clinical Evaluator Training Grp and PTC124-GD-007-Study Grp and ACT DMD Study Grp
Journal of comparative effectiveness research, ISSN 2042-6305, 08/2020, Volume 9, Issue 14, pp. 973 - 984
Life Sciences & Biomedicine | Health Care Sciences & Services | Science & Technology
Journal Article
Details down arrow
12. Full Text Is clostridium difficile associated with relapse of inflammatory bowel disease? results from a retrospective and prospective cohort study in the Netherlands
by Masclee, G.M and Penders, J and Jonkers, D.M.A.E and Wolffs, P.F.G and Pierik, M.J
Inflammatory bowel diseases, ISSN 1078-0998, 09/2013, Volume 19, Issue 10, pp. 2125 - 2131
CROHNS-DISEASE | TOXIN | Clostridium difficile | real-time polymerase chain reaction | ULCERATIVE-COLITIS | ACTIVITY INDEXES | inflammatory bowel disease | exacerbation | REAL-TIME PCR | MEDICAL THERAPY | EFFICACY END-POINTS | CLINICAL-TRIALS | RESISTANCE | INFECTION | bacterial pathogen | Exacerbation | Inflammatory bowel disease | Bacterial pathogen | Real-time polymerase chain reaction | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Severity of Illness Index | Recurrence | Prognosis | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Male | Colitis, Ulcerative - pathology | Enterocolitis, Pseudomembranous - microbiology | Clostridium difficile - pathogenicity | Enterocolitis, Pseudomembranous - complications | Feces - microbiology | Netherlands | Colitis, Ulcerative - etiology | Crohn Disease - pathology | Adult | Female | Retrospective Studies | Enterocolitis, Pseudomembranous - diagnosis | Chronic Disease | Crohn Disease - etiology | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights